V 160Alternative Names: Cytomegalovirus vaccine - V160; V-160
Latest Information Update: 23 Mar 2016
At a glance
- Originator Merck & Co
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cytomegalovirus infections
Most Recent Events
- 28 Nov 2013 Preclinical trials in Cytomegalovirus infections in USA (IM)
- 28 Nov 2013 Merck plans a phase I trial for Cytomegalovirus infections in USA (NCT01986010)